A Multicenter, Randomized, Double-blind, Placebo-controlled, 52-weeks Study to Demonstrate the Efficacy, Safety and Tolerability of Subcutaneous Secukinumab Injections With 2 mL Pre-filled Syringes (300 mg) in Adult Subjects With Moderate to Severe Plaque Psoriasis
Phase of Trial: Phase III
Latest Information Update: 24 Apr 2017
At a glance
- Drugs Secukinumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms ALLURE
- Sponsors Novartis Pharmaceuticals
- 19 Apr 2017 Planned End Date changed from 1 Sep 2018 to 23 Aug 2018.
- 19 Apr 2017 Planned primary completion date changed from 1 Sep 2018 to 12 Oct 2017.
- 19 Apr 2017 Status changed from not yet recruiting to recruiting.